Talk title: "Improving ALS therapeutic trial endpoints"
Stephanie Fradette, PharmD, is a Senior Medical Director in Clinical Development. In her role, Stephanie oversees Biogen’s amyotrophic lateral sclerosis portfolio. She also leads development of tofersen, Biogen’s investigational therapy for SOD1-ALS. Stephanie has spent the last 13 years in Research and Development at Biogen. Prior to her work in ALS, Stephanie supported Spinraza® (nusinersen), the first therapy approved for the treatment of spinal muscular atrophy. Stephanie obtained her doctorate in pharmacy from Northeastern University and completed a post-doctoral fellowship at Biogen.